Download a printable version of the 2007 Program Announcement.
The 2007 Breast Cancer Symposium
Integrating Emerging Science into Clinical Practice
Friday, September 7, 2007
Exhibit Hall Open
7:00 AM – 6:30 PM
Continental Breakfast Provided
7:00 AM — 8:00 AM
Welcome
7:45 AM — 8:00 AM
General Session I: The Role of Estrogen in Breast Cancer
8:00 AM — 9:30 AM
Co-Chair — Lori J. Goldstein, MD — Fox Chase Cancer Center
Co-Chair — David A. Mankoff, MD — Seattle Cancer Care Alliance
- Estrogen: Carcinogen, Growth Promoter, or Treatment?
Paul E. Goss, MD, PhD — Massachusetts General Hospital Cancer Center
Progesterone Receptor: The Forgotten Target
Douglas Yee, MD — University of Minnesota Cancer Center
Non-Oncologic Consequences of Estrogen Depletion
Michael L. Krychman, MD — Memorial Sloan-Kettering Cancer Center
What is Hormone Responsive?
Donald Craig Allred, MD — Washington University School of Medicine
Imaging Hormonally-Dependent Breast Cancer
Hannah M. Linden, MD — Seattle Cancer Care Alliance
General Session II: Plenary Lecture: The Impact of Radiation on Long-Term Survival: Local Control Matters
9:30 AM — 10:15 AM
Chair — Robert W. Carlson, MD — Stanford University
- The Impact of Local Treatment on Long-Term Survival: Local Control Matters
Jay R. Harris, MD — Dana-Farber Cancer Institute
Avoidance of Cardiac Toxicity
Lori J. Pierce, MD — University of Michigan School of Medicine
Break
10:15 AM — 10:30 AM
Oral Abstract Presentation Session A
10:30 AM — 12:00 PM
Co-Chair — Larry Norton, MD — Memorial Sloan-Kettering Cancer Center
Co-Chair — Emiel J. Rutgers, MD, PhD — Netherlands Cancer Institute
General Poster Session A (Boxed Lunch Provided)
12:00 PM — 12:45 PM
Selected topic–related abstracts will be on display, with the authors available for informal discussion.
ASCO Gianni Bonadonna Breast Cancer Award & Lecture
12:45 PM — 1:30 PM
Break
1:30 PM — 1:45 PM
General Session III: Current Controversies
1:45 PM — 3:30 PM
Co-Chair — Timothy J. Whelan, BM, BCh, MSc — Cancer Care Ontario, Juravinski Cancer Center
Co-Chair — Eric P. Winer, MD — Dana-Farber Cancer Institute
- Why is Radiation Therapy Controversial in Ductal Carcinoma in Situ?
Beryl McCormick, MD — Memorial Sloan-Kettering Cancer Center
Why Don't We Know Who Needs Ovarian Suppression as Adjuvant Therapy?
Sandra M. Swain, MD — Washington Cancer Institute
Why is Magnetic Resonance Imaging Controversial in Planning Surgery and Screening for Second Breast Cancers?
Kimberly J. Van Zee, MD — Memorial Sloan-Kettering Cancer Center
Why is Anthracycline Use Controversial?
Angelo Di Leo, MD — Hospital of Prato
Break
3:30 PM — 3:45 PM
General Session IV: Clinical and Research Issues in Pathology
3:45 PM — 5:30 PM
Co-Chair — Daniel F. Hayes, MD — University of Michigan Medical Center
Co-Chair — William Fraser Symmans, MD — M.D. Anderson Cancer Center
- Processing
Sarah Pinder, PhD — Guy's Hospital, London
Gene Expression Profiling
Christos Sotiriou, MD, PhD — Jules Bordet Institute
Imaging/Pathology Correlations
Constance D. Lehman, MD — Seattle Cancer Care Alliance
Sentinel Node Processing and Interpretation
Baljit Singh, MD , MBBS — New York University Medical Center
Premalignant Lesions: Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, and Other Lesions that Increase the Risk of Invasive Breast Cancer
Laura C. Collins, MD — Beth Israel Deaconess Medical Center
What is Triple Negative Breast Cancer?
Lisa A. Carey, MD — University of North Carolina
General Poster Session B (Wine and Cheese Provided)
5:30 PM — 6:30 PM
Selected topic–related abstracts will be on display, with the authors available for informal discussion.
Saturday, September 8, 2007
Exhibit Hall Open
7:00 AM – 1:00 PM
General Poster Session C (Continental Breakfast Provided)
7:00 AM — 8:00 AM
Welcome
7:45 AM — 8:00 AM
General Session V: Local Regional Management
8:00 AM — 9:45 AM
Co-Chair — Silvia Chiara Formenti, MD — New York University Medical Center
Co-Chair — Funda Meric-Bernstam, MD — M.D. Anderson Cancer Center
- Is Axillary Dissection Needed in Node (+) Breast Cancer?
Mehra Golshan , MD — Brigham and Women's Hospital
Is There a Role for Local Treatment in Metastatic Breast Cancer?
Seema Khan, MD — Northwestern Memorial Hospital
Is There an Optimal Way of Integrating Postmastectomy Radiation Therapy and Reconstruction?
Abram Recht, MD — Beth Israel Deaconess Medical Center
Partial Breast Irradiation: Biological Underpinnings and Clinical Data
Frank A. Vicini, MD — William Beaumont Hospital
Does Subtype and Genotype Influence Local Treatment Decisions?
Bruce G. Haffty, MD — Robert Wood Johnson Medical School
Can We Use Early Response Assessment to Guide Pre-operative Therapy?
Harold J. Burstein, MD — Dana-Farber Cancer Institute
Break
9:45 AM — 10:00 AM
General Session VI: HER2 Positive Breast Cancer
10:00 AM — 11:45 AM
Co-Chair — Clifford Hudis, MD — Memorial Sloan-Kettering Cancer Center
Co-Chair — Edith Perez, MD — Mayo Clinic Jacksonville
- Biology of HER2 (+) Disease/Role of ER
Mark D. Pegram, MD — University of California, Los Angeles, Geffen School of Medicine
HER2 Testing
Antonio C. Wolff, MD — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
What is the Role of Chemotherapy with Trastuzumab?
Ian E. Smith, MD — Royal Marsden Hospital
Tyrosine-Kinase Inhibitors
Francisco J. Esteva, MD, PhD — M.D. Anderson Cancer Center
Other Anti-HER2 Agents
Jose Baselga, MD — Hospital Vall D'Hebron
Imaging and HER2 Therapy: Targeting and Response
Steven M. Larson, MD — Memorial Sloan-Kettering Cancer Center
General Poster Session D (Box Lunches Provided)
11:45 AM — 12:45 PM
General Session VII: Keynotes on Disparities
12:45 PM — 2:00 PM
Co-Chair — Otis W. Brawley, MD — Emory University Winship Cancer Institute
Co-Chair — Lisa A Newman, MD, MPH — University of Michigan
- Biology Differences in Breast Cancer Across Diverse Populations Within and Outside of the United States
Olufunmilayo I. Olopade, MD, MBBS — University of Chicago Pritzker School of Medicine
Socioeconomic Barriers to Optimal Care
Lisa A. Newman, MD, MPH — University of Michigan
Oral Abstract Presentation Session B
2:00 PM — 3:30 PM
Co-Chair — Anees B. Chagpar, MD — University of Louisville
Co-Chair — Nancy E. Davidson, MD — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Break
3:30 PM — 3:45 PM
General Session VIII: Preoperative Therapy: Who and Why?
3:45 PM — 5:30 PM
Co-Chair — Hope S. Rugo, MD — University of California, San Francisco Comprehensive Cancer Center
Co-Chair — JoAnne Zujewski, MD — National Institutes of Health
- Preoperative Therapy for Research
Laura Esserman, MD, MBA — University of California, San Francisco Comprehensive Cancer Center
Pre versus Postoperative Trial Results: What are the Benefits?
Julie Gralow, MD — Seattle Cancer Care Alliance
Challenges for Radiation Therapy After Preoperative Therapy
Thomas A. Buchholz, MD — M.D. Anderson Cancer Center
How Do We Use Sentinel Node Techniques?
Eleftherios P. Mamounas, MD — Aultman Cancer Center
Preoperative Hormone Therapy Trials
Matthew J. Ellis, MBBChir, PhD — Washington University
|
